Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: Potential mechanisms for heightened prothrombotic potential

Journal of the American College of Cardiology

Volumn 34, Issue 4, 1999, Pages 1020-1027

  Becker, Richard C ^a   Spencer, Frederick A ^a   Li, Youfu ^a   Ball, Steven P ^a   Ma, Yunsheng ^a   Hurley, Thomas ^a   Hebert, James ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE HEART FAILURE; ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; REBOUND; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBIN TIME; THROMBOCYTE AGGREGATION; VASCULAR RESISTANCE;

ADULT; AGED; ANGINA, UNSTABLE; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LIPOPROTEINS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PARTIAL THROMBOPLASTIN TIME; PILOT PROJECTS; SUBSTANCE WITHDRAWAL SYNDROME; THROMBIN;

EID: 0033212936     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00322-8     Document Type: Article

References (53)

1. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Clinical practice guideline number 10. AHCPR Publication No. 94-0602. Rockville (MD): Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, US Department of Health and Human Services, 1994:65.
2. Hirsh J. Heparin. N Engl J Med 1991;324:1565-74.
3. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-30.
4. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-11.
5. Falk E. Unstable angina and fatal outcome: coronary thrombosis leading to infarction and/or sudden death. Circulation 1985;4:699-708.
6. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-5.
7. Conrad Smith AJ, Holt RE, Fitzpatrick K, et al. Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. Am Heart J 1996;131:434-9.
8. Gold HK, Torres F, Garabedian H, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993;21:1039-47.
9. Garabidian HD, Gold HK, Newell JB, et al. Accelerated thrombin generation during anticoagulation in patients with unstable angina pectoris [correspondence]. Blood 1994;83:1155.
10. Zoldhelyi P, Bichler J, Owen WG, et al. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994;90:2671-8.
11. Oltrona L, Eisenberg PR, Lasala JM, et al. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996;94:2064-71.
12. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-35.
13. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993;91:1877-83.
14. Mann KG. The coagulation explosion. Ann NY Acad Sci 1994;714:265-9.
15. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
16. Eidt JH, Allison P, Noble S, et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989;84:18-27.
17. Gast A, Tschopp TB, Baumgartner HR. Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. Arterioscler Thromb 1994;14:1466-74.
18. Rho R, Tracy RP, Bovill EG, et al. Plasma markers of procoagulant activity among individuals with coronary artery disease. J Thromb Thrombolysis 1995;2:239-43.
19. Becker RC, Tracy RP, Bovill EG, et al., for the TIMI III Thrombosis and Coagulation Study Group. Surface 12-lead electrocardiographic findings and plasma markers of thrombin activity and generation in patients with myocardial ischemia at rest. J Thromb Thrombolysis 1994;1:101-7.
20. Biasucci LM, Liuzzo G, Caligiuri G, et al. Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina. Circulation 1996;93:2121-7.
21. Szczeklik A, Dropinski J, Radwan J, Krzanowski M. Persistent generation of thrombin after acute myocardial infarction. Arterioscler Thromb 1992;12:548-53.
22. Merlini PA, Bauer KA, Oltrona L, et al. Persistant activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-8.
23. Becker RC, Hurley T, Ma Y, Hebert JR. Evolution of direct thrombin antagonists: acknowledging potential limitations. J Thromb Thrombolysis 1996;3:23-7.
24. Ofosu FA, Gray E. Mechanisms of action of heparin: applications to the development of derivatives of heparin and heparinoids with antithrombin properties. Semin Thromb Haemost 1988;14:9-17.
25. Gallino A, Haeberli A, Hess T, et al. Fibrin formation and platelet aggregation in patients with acute myocardial infarction: effects of intravenous and subcutaneous low dose heparin. Am Heart J 1986;12:285-90.
26. Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995;92:962-7.
27. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;236:252-318.
28. Hatton MWC, Moar SL, Richardson M. Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface. Correla-tion of uptake of fibrinogen and antithrombin III with thrombin generation by the exposed subendothelium. Am J Pathol 1989;135:499-508.
29. Hatton MWC, Southward SMR, Ross-Ouellet B, et al. An increased uptake of prothrombin, antithrombin, and fibrinogen by the rabbit balloon-deendothelialized aorta surface in vivo is maintained until reendothelialization is complete. Arterioscler Thromb Vase Biol 1996;16:1147-55.
30. Speidel CM, Eisenberg PR, Ruf W, et al. Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits. Circulation 1995;92:3323-30.
31. Tracy PB. Regulation of thrombin generation at cell surfaces. Semin Thromb Hemost 1988;14:227-33.
32. Marmur JD, Thiruvikraman SV, Fyfe BS, et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996;94:1226-32.
33. Annex BH, Denning SM, Channon KM, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995;91:619-22.
34. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997;95:594-9.
35. McKenzie CR, Abendschein DR, Eisenberg PR. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler Thromb Vase Biol 1996;16:1285-91.
36. van't Veer C, Hackeng TM, Delahaye C, et al. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor. Blood 1994;84:1132-9.
37. Kaiser B, Hoppensteadt DA, Jeske W, et al. Inhibitory effects of TFPI of thrombin and factor Xa generation in vitro-modulatory action of glycosaminoglycans. Thromb Res 1994;75:609-19.
38. Sprecher CA, Kisiel W, Mathewes S, Foster DC. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci USA 1994;91:3353-60.
39. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor. Thromb Res 1988;50:803-13.
40. Harenberg J, Siegele M, Dempfle CE, Stehle G, Heene DL. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins. Thromb Haemost 1993;6:942-5.
41. Lindahl AK, Abildgaard U, Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991;64:155-68.
42. Hansen, JB, Huseby KR, Huseby NE, et al. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperhpoproteinemia. Artenoscler Thromb Vase Biol 1995;15:879-85.
43. Balentin S, Lamkjar A, Østergaard P, Nielsen JI, Norfang O. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994;75:173-83.
44. Valentin S, Norfang O, Bregengard C, Wildgoose P. Evidence that the C-terminus for tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemost 1992;68:33-6.
45. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor (TFPI) is restricted to its free form in human plasma [abst]. Thromb Haemost 1995;73:1260.
46. Valentin S, Østergaard P, Kristensen H, Norfang O. Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin. Blood Coag Fibrinolysis 1992;3:221-2.
47. Sandset PM. Tissue factor pathway inhibitor (TFPI) - an update. Haemostasis 1996;26 Suppl 4:154-65.
48. Hanson J-B, Sandset PM, Huseby KR, Huseby N-E. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion or heparin in man. Thromb Haemost 1996;76:703-9.
49. Becker RC, Ball SP, Eisenberg P, et al., for the Antithrombotic Therapy Consortium Investigators. A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Am Heart J 1999;137:59-71.
50. Bregengaard C, Nordfang O, Ostergaard P, et al. Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemost 1993;70:454-7.
51. DeCristofaro R, DeCandia E, Landolfi R. Effect of high- and low-molecular weight heparins on thrombin-thrombomodulin interaction and protein C activation. Circulation 1998;98:1297-1301.
52. ACC/AHA Committee on Management of Acute MI. ACC/AHA Guidelines for the Management of Patients with Acute MI. J Am Coll Cardiol 1996;28:1328-428.
53. Hirsh J, Rascke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring efficacy and safety. Chest 1995;108 Suppl:258S-75S.